Andreas Mantoulidis
Company: Boehringer Ingelheim
Job title: Research Laboratory Head
Seminars:
Targeting KRAS Mutations Beyond G12C: Development & Therapeutic Potential of ACBI3 for Comprehensive KRAS Degradation & Tumour Regression 1:45 pm
The first drugs targeting KRAS G12C have been approved, but undruggable mutants and secondary mutations still pose a challenge in treating KRAS mutant cancers Starting from a fragment first approach, ACBI3 was developed through structure guided and optimisation of biophysics ACBI3 potently degrades most prevalent oncogenic KRAS variants, sparing H- and NRAS and has demonstrated…Read more
day: Day 1, Track 2, PM
Chair’s Closing Remarks 5:15 pm
day: Day 1, PM